---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-055717"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T01:23:29.156845+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics launches expanded access program for zervimesine in DLB

## Summary
- Anonymous philanthropic donation from family of DLB patient who was in SHIMMER study funds the program.
- Open-label EAP: 100 mg oral zervimesine daily for ~1 year; targets ~30 patients initially across 8 U.S. sites.
- First site activated: Banner Sun Health Research Institute; Dr. David Shprecher site investigator; Dr. James Galvin lead investigator.
- EAP open to eligible SHIMMER completers and other mild-to-moderate DLB patients meeting criteria.
- Company aims to start providing zervimesine this month (June 2025).

## SEC filing metadata
- accession: 0001104659-25-055717
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465925055717/0001104659-25-055717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465925055717/tm2516905d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-055717
- JSON: https://secwatch.observer/filing/0001104659-25-055717.json
- Plain text: https://secwatch.observer/filing/0001104659-25-055717.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.